SI-BONE, Inc. (NASDAQ:SIBN) Shares Acquired by Barclays PLC

Barclays PLC raised its position in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 190.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 96,623 shares of the company's stock after acquiring an additional 63,402 shares during the period. Barclays PLC owned approximately 0.23% of SI-BONE worth $1,350,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SIBN. FMR LLC grew its holdings in shares of SI-BONE by 103.6% during the 3rd quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after purchasing an additional 1,198 shares during the period. Canada Pension Plan Investment Board acquired a new position in SI-BONE during the second quarter valued at approximately $61,000. Walleye Capital LLC purchased a new stake in SI-BONE during the third quarter worth approximately $144,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of SI-BONE by 24.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company's stock worth $138,000 after acquiring an additional 2,108 shares in the last quarter. Finally, Arizona State Retirement System raised its stake in shares of SI-BONE by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company's stock valued at $141,000 after acquiring an additional 903 shares during the period. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at SI-BONE

In other news, CFO Anshul Maheshwari sold 2,439 shares of the business's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.68, for a total value of $30,926.52. Following the completion of the sale, the chief financial officer now owns 194,623 shares of the company's stock, valued at approximately $2,467,819.64. The trade was a 1.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anthony J. Recupero sold 3,305 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total transaction of $44,881.90. Following the transaction, the insider now directly owns 233,412 shares in the company, valued at $3,169,734.96. The trade was a 1.40 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,679 shares of company stock valued at $276,439. Insiders own 3.90% of the company's stock.

Analyst Ratings Changes

SIBN has been the subject of a number of research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 price target on shares of SI-BONE in a research report on Wednesday, November 20th. Truist Financial upped their target price on SI-BONE from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $23.00.

SI-BONE Stock Down 0.9 %

Shares of SI-BONE stock traded down $0.12 during trading hours on Friday, hitting $13.72. 329,580 shares of the company's stock traded hands, compared to its average volume of 380,272. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $21.64. The company has a market cap of $575.39 million, a PE ratio of -14.91 and a beta of 1.20. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The stock has a 50 day simple moving average of $13.46 and a 200-day simple moving average of $14.09.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.